ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

CyThera, Inc., headquartered in San Diego, CA, is a biotechnology company focused on developing cell replacement therapies for the treatment of human degenerative diseases. The company's proprietary technology platform enables the expansion and proliferation of functional human cells that can be used to treat human degenerative disease.

Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers. Their lead AMPK activator compound O304 is currently in Phase IIa clinical trial.

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.

Reliance Life Sciences is a diverse and integrated biotechnology initiative of the Reliance Group of companies. The Reliance Group is India’s largest private sector enterprise, with annual revenues of US$ 66.8 billion. The Group’s activities span oil and gas exploration and production, petroleum refining, petrochemicals, polyester, plastics, organized retailing and telecom. The Group’s flagship company Reliance Industries Limited is the largest private sector company and a Fortune Global 500 company. Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited. RLS was established to develop business opportunities in medical biotechnology with key initiatives in biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical research and molecular diagnostics.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Janssen Biotech, Inc. has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative "firsts," Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology, and nephrology. With the same unwavering passion for new challenges, They dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

Guangzhou Erlijian Biotechnology Co., Ltd., established on 2021-12-31, Business scope includes data processing services;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software development;Medical Research and Experimental Development;Biomass Energy Technology Services;Biochemical product technology research and development;R&D and application of cell technology;Sales of hygiene products and single-use medical products;Development of Human Gene Diagnosis and Therapy Technology;;Inspection and testing service;

InGeneron is a clinical stage cell therapy company. We believe that evidence-based regenerative therapy will redefine the health care experience. Its system is designed to enable doctors to heal patients safely and quickly by unlocking and using the healing potential of their own regenerative cells. Founded in 2006, we are a Houston-headquartered, privately held company that was formed to innovate cell-based technologies for health care and life science research. The work of our scientists and doctors in the field of the stem and regenerative cell research has enabled us to develop a regenerative cell therapy product platform for multiple potential applications. This work has yielded numerous peer-reviewed publications and studies on the use of autologous adult stem cells – those that are extracted from and reintroduced into the same person – to promote healing.

Guangzhou Puma Health Consulting Co., Ltd., established on 2016-11-14, Business scope includes technical services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Remote Health Management Services;Information Consulting Service(Not including licensing information consulting services);Health Consulting Services(Does not include medical services);Medical Research and Experimental Development;Sales of Class II Medical Devices;Sales of Class I Medical Devices;

Hanhai Boxing is a biotech company that develops anti-cancer drug PD1 monoclonal antibodies that can treat a variety of solid tumors. Compared with similar products on the market or in clinical trials, this product has the advantages of high purity, high affinity, low cost, independent intellectual property rights, etc. The annual sales revenue of the product is expected to reach billions of dollars after the product is launched. The company has successively won the "National High-tech Enterprise", "Hewu Clam Major Talent and Achievement Project", "National Genetic Testing Application Demonstration Center", "International R&D Service Outsourcing Innovation Platform", "Hefei Intellectual Property Demonstration Enterprise", "Anhui Province" AAAA-level credit enterprise", "A-level contract and trustworthy enterprise" and many other honors. The company has been reported by many well-known media such as CCTV-1 News Network, Anhui Satellite TV News Network, China Daily, People's Daily, and Guangming Daily.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.